ACACB and neoplasm: The xenograft mouse data further showed that human BRAFV600E tumor cells became less responsive to vemurafenib within two weeks, and ultimately exhibited increased tumor growth when the Acetyl-CoA Carboxylase 2 gene (ACC2) was knocked down.